These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 17263127)

  • 1. Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.
    Morris SR; Carey LA
    Oncology (Williston Park); 2006 Dec; 20(14):1763-71; discussion 1771-2, 1774-6. PubMed ID: 17263127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Her2-positive breast cancer: herceptin and beyond.
    Dean-Colomb W; Esteva FJ
    Eur J Cancer; 2008 Dec; 44(18):2806-12. PubMed ID: 19022660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
    Shak S
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
    Dank M
    Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.
    Spector NL; Blackwell KL
    J Clin Oncol; 2009 Dec; 27(34):5838-47. PubMed ID: 19884552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review.
    Tokuda Y; Suzuki Y; Saito Y; Umemura S
    Breast Cancer; 2009; 16(4):295-300. PubMed ID: 19609647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant trastuzumab for HER2-positive early breast cancer.
    Palmieri FM; Myatt CV; Perez EA
    Clin J Oncol Nurs; 2010 Jun; 14(3):326-36. PubMed ID: 20529794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2-positive breast cancer: beyond trastuzumab.
    Murphy CG; Fornier M
    Oncology (Williston Park); 2010 Apr; 24(5):410-5. PubMed ID: 20480738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.
    Baselga J; Tripathy D; Mendelsohn J; Baughman S; Benz CC; Dantis L; Sklarin NT; Seidman AD; Hudis CA; Moore J; Rosen PP; Twaddell T; Henderson IC; Norton L
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):78-83. PubMed ID: 10482197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
    Nahta R; Yu D; Hung MC; Hortobagyi GN; Esteva FJ
    Nat Clin Pract Oncol; 2006 May; 3(5):269-80. PubMed ID: 16683005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved prognosis by trastuzumab of women with HER2-positive breast cancer compared with those with HER2-negative disease.
    Ferretti G; Fabi A; Felici A; Papaldo P
    J Clin Oncol; 2010 Jul; 28(20):e337; author reply e338-9. PubMed ID: 20479395
    [No Abstract]   [Full Text] [Related]  

  • 14. Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.
    Montemurro F; Redana S; Viale G; Sanna G; Donadio M; Valabrega G; del Curto B; Bottini A; Botti G; dei Tos AP; Jacomuzzi ME; Di Bonito M; Danese S; Clavarezza M; Kulka J; Di Palma S; Durando A; Sapino A; Aglietta M
    Clin Breast Cancer; 2008 Oct; 8(5):436-42. PubMed ID: 18952558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Breast cancer and herceptin].
    Cornez N; Piccart MJ
    Bull Cancer; 2000 Nov; 87(11):847-58. PubMed ID: 11125293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Herceptin-based therapy for breast cancer].
    Tokuda Y; Saito Y; Suzuki Y
    Nihon Rinsho; 2006 Mar; 64(3):540-5. PubMed ID: 16529047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer.
    Bedard PL; Piccart-Gebhart MJ
    Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S157-65. PubMed ID: 19158036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of care.
    Brufsky A
    Am J Clin Oncol; 2010 Apr; 33(2):186-95. PubMed ID: 19675448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.
    Molina MA; Codony-Servat J; Albanell J; Rojo F; Arribas J; Baselga J
    Cancer Res; 2001 Jun; 61(12):4744-9. PubMed ID: 11406546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients.
    Sperinde J; Jin X; Banerjee J; Penuel E; Saha A; Diedrich G; Huang W; Leitzel K; Weidler J; Ali SM; Fuchs EM; Singer CF; Köstler WJ; Bates M; Parry G; Winslow J; Lipton A
    Clin Cancer Res; 2010 Aug; 16(16):4226-35. PubMed ID: 20664024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.